{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:46:47Z","timestamp":1791956807817,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01428-y","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:15:35Z","timestamp":1789139735000},"page":"2927-2938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dengue Vodcast: Insights from Recent Infectious Disease Congresses"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-9446","authenticated-orcid":false,"given":"Marco Aur\u00e9lio P.","family":"S\u00e1fadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"1428_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1473-3099(25)00382-2","volume":"26","author":"OT Ranzani","year":"2024","unstructured":"Ranzani OT, Lazar Neto F, Mareto LK, et al. Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in S\u00e3o Paulo, Brazil: a test-negative, case\u2013control study. Lancet Infect Dis. 2024;26:91\u2013100. https:\/\/doi.org\/10.1016\/S1473-3099(25)00382-2.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1428_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050483","volume":"13","author":"A Wilder-Smith","year":"2025","unstructured":"Wilder-Smith A, Cherian T, Hombach J. Dengue vaccine development and deployment into routine immunization. Vaccines (Basel). 2025;13(5):483. https:\/\/doi.org\/10.3390\/vaccines13050483.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"1428_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12020032","volume":"12","author":"EC Okoye","year":"2024","unstructured":"Okoye EC, Mitra AK, Lomax T, Nunaley C. Dengue fever epidemics and the prospect of vaccines: a systematic review and meta-analysis using clinical trials in children. Diseases. 2024;12(2):32. https:\/\/doi.org\/10.3390\/diseases12020032.","journal-title":"Diseases"},{"issue":"13","key":"1428_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","volume":"373","author":"SR Hadinegoro","year":"2015","unstructured":"Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa1506223.","journal-title":"N Engl J Med"},{"issue":"2","key":"1428_CR5","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","volume":"12","author":"V Tricou","year":"2024","unstructured":"Tricou V, Yu D, Reynales H, et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2024;12(2):e257\u201370. https:\/\/doi.org\/10.1016\/S2214-109X(23)00522-3.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"1428_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002243","volume":"7","author":"CY Huang","year":"2013","unstructured":"Huang CY, Kinney RM, Livengood JA, et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7(5):e2243. https:\/\/doi.org\/10.1371\/journal.pntd.0002243.","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"1428_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2301790","volume":"390","author":"EG Kall\u00e1s","year":"2024","unstructured":"Kall\u00e1s EG, Cintra MAT, Moreira JA, et al. Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults. N Engl J Med. 2024;390(5):397\u2013408. https:\/\/doi.org\/10.1056\/NEJMoa2301790.","journal-title":"N Engl J Med"},{"issue":"42","key":"1428_CR8","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","volume":"29","author":"AP Durbin","year":"2011","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine. 2011;29(42):7242\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.023.","journal-title":"Vaccine"},{"key":"1428_CR9","unstructured":"Escudero I, Sirivichayakul C, Acosta CJ, et al. Evaluation of booster dose of the tetravalent dengue vaccine TAK-003 in healthy children in dengue endemic regions (DEN-301). Presented at WSPID 2025 (ID 437). https:\/\/wspid2025.com\/abstract-e-book\/. Accessed Jun 2026."},{"key":"1428_CR10","unstructured":"Parra MM, Escudero I, Tricou V, et al. Long-term safety before and after booster of tetravalent dengue vaccine TAK-003 in healthy adolescents in dengue nonendemic Mexico (abstract 6294). https:\/\/plan.core-apps.com\/astmh25\/abstract\/e342425e-bf37-4778-8d04-699c12a9ebc0. Accessed Jun 2026."},{"key":"1428_CR11","unstructured":"Escudero I, Tricou V, Tuboi S, et al. Long-term safety before and after booster of tetravalent dengue vaccine TAK-003 in healthy adults in dengue nonendemic United States (abstract 6649). https:\/\/plan.core-apps.com\/astmh25\/abstract\/d33d3f59-5cc3-420d-8303-e696167b2cad. Accessed Jun 2026"},{"key":"1428_CR12","unstructured":"S\u00e1fadi MA. Dengue overview and the current situation in Brazil. Presented at WSPID 2025 (0470\/ID 1130). Supported symposium (no abstract available)."},{"key":"1428_CR13","unstructured":"D'Agostini TL. One-year follow-up evaluation of TAK-003 dengue vaccine effectiveness against symptomatic disease and hospitalization in adolescents during the 2024\u20132025 outbreak in S\u00e3o Paulo, Brazil. Presented at ESPID 2026 (abstract LBAO-001). https:\/\/cslide.ctimeetingtech.com\/espid26\/attendee\/person\/3122. Accessed Jul 2026."},{"key":"1428_CR14","unstructured":"Rauscher M, Youard Z, Tricou V, Franco M, Zent O. Two years of post-marketing experience with Takeda's live-attenuated dengue vaccine\u2014a safety data review. Presented at WSPID 2025 (ID 448). https:\/\/wspid2025.com\/abstract-e-book\/. Accessed Jun 2026"},{"key":"1428_CR15","unstructured":"Tricou V, Brose M, Nwe HH, et al. Innovative design and implementation tools for a post-approval dengue vaccine effectiveness study requiring primary data collection (DEN-401). Presented at WSPID 2025 (ID 109). https:\/\/wspid2025.com\/abstract-e-book\/. Accessed Jun 2026."},{"key":"1428_CR16","unstructured":"Mandaric S, Friberg H, Messer W, et al. An open-label phase 2 trial in flavivirus-naive and dengue-immune us healthy adults: humoral and T cell responses to a tetravalent dengue vaccine (TAK-003). Presented at ASTMH 2025 (abstract 6296). https:\/\/plan.core-apps.com\/astmh25\/abstract\/d908d09c-a373-47b4-839d-318d3b7901f9. Accessed Jun 2026."},{"key":"1428_CR17","unstructured":"Gottardo R, Tricou V, Nascimento EJM, Sharma M. Beyond neutralization: a comprehensive framework for evaluating humoral immunity induced by the TAK-003 dengue vaccine. Presented at ASTMH 2025 (abstract 6292). https:\/\/plan.core-apps.com\/astmh25\/abstract\/80939e33-02d7-45da-a57b-622c0cfd1a97. Accessed Jun 2026."},{"key":"1428_CR18","unstructured":"Nascimento EJM, Tsuji I, Watkins H, et al. Differentiating humoral immunogenicity driven by a live-attenuated tetravalent dengue vaccine from prior dengue virus exposure: key highlights of immunological advantage of TAK-003 vaccination. Presented at ASTMH 2025 (abstract 6297). https:\/\/plan.core-apps.com\/astmh25\/abstract\/8588fbad-8105-4532-9141-ee08aade34c0. accessed Jun 2026."},{"key":"1428_CR19","unstructured":"Nogueira ML, Moreira JA, Patino EG, et al. Five-year efficacy and safety of a live, attenuated tetravalent dengue vaccine produced by Instituto Butantan: results from a phase 3 clinical trial in children, adolescents, and adults. Presented at ASTMH 2025 (abstract 6645). https:\/\/plan.core-apps.com\/astmh25\/abstract\/7aacb4d1-c825-4062-9d6c-c640b2cdfc80. Accessed Jun 2026."},{"key":"1428_CR20","unstructured":"Koka VSP, Wende A. NA on the go: a rapid, field-deployable DNA\/RNA extraction workflow for disease vectors. Presented at ASTMH 2025 (abstract 6770). https:\/\/plan.core-apps.com\/astmh25\/abstract\/3ca9bf30-53e1-47c9-a71d-a2bfd88f1237. Accessed Jun 2026."},{"key":"1428_CR21","unstructured":"Dousti K, Ceruti A, Abd El Wahed A, et al. Urban vs. hospital settings: which environment poses a higher risk of vector-borne diseases? Mosquito monitoring and species identification in Bissau, Guinea-Bissau. Presented at ASTMH 2025 (abstract 6221). https:\/\/plan.core-apps.com\/astmh25\/abstract\/a41e2058-2e34-49ef-929a-388bd883c893. Accessed Jun 2026."},{"key":"1428_CR22","unstructured":"Niyituma E, Kiwelu GL, Maige JL, Silayo JL, Kiware S, Hakizimana E. Improving vector surveillance through digital innovation: impact and lessons from VBDs360 in Rwanda. Presented at ASTMH 2025 (abstract 6704). https:\/\/plan.core-apps.com\/astmh25\/abstract\/6106f1bb-6a8a-47d8-a544-e241e9b528fd. Accessed Jun 2026."},{"key":"1428_CR23","unstructured":"Ong SQ, Ahmad SAJ, Lee PC, et al. Mosquito-borne diseases in North Borneo Sabah Malaysia: Development of a machine learning pipeline to support vector detection and risk factor assessment. Presented at ASTMH 2025 (abstract 6056). https:\/\/plan.core-apps.com\/astmh25\/abstract\/1de082b6-4fa4-4ab5-a4e9-deb0e747b8c6. Accessed Jun 2026."},{"key":"1428_CR24","unstructured":"Martin EM, McNamara D, Paris T, Martini X. Evaluating the impact of light emitting diodes (LEDs) wavelength on male and female Aedes aegypti attraction to light. Presented at ASTMH 2025 (abstract 7382). https:\/\/plan.core-apps.com\/astmh25\/abstract\/a77f0c7d-2ebc-472a-a863-cfd9dd4b7a90. Accessed Jun 2026."},{"key":"1428_CR25","unstructured":"Angelico JW, Amaro IA, Pitcher S, et al. Do female-derived proteins associate with sperm in the dengue vector Aedes aegypti? Presented at ASTMH 2025 (abstract 7371). https:\/\/plan.core-apps.com\/astmh25\/abstract\/ed4d4a7c-fb6c-4128-a8a7-4a646f65d134. Accessed Jun 2026."},{"key":"1428_CR26","unstructured":"Birhanie SK, Brown M. Rapid reduction in Aedes aegypti population following sterile insect application in the West Valley region of southern California. Presented at ASTMH 2025 (abstract 7169). https:\/\/plan.core-apps.com\/astmh25\/abstract\/4ca2feda-28c3-491d-be7a-4b6870b155dd. Accessed Jun 2026."},{"key":"1428_CR27","unstructured":"Lopez Del Amo V. CRISPR-based strategies for managing mosquitoes and fighting vector-borne diseases. Presented at ASTMH 2025 (session 40). https:\/\/plan.core-apps.com\/astmh25\/event\/485ac1333362eb3f472c56c885b3d1f5. Accessed Jun 2026."},{"key":"1428_CR28","unstructured":"Allan RJ, Kamal M, Ahmad S, et al. Evaluating novel multi-vector control tools for humanitarian crises: the entomological efficacy of attractive toxic sugar baits (ATSB) in Northern Nigeria. Presented at ASTMH 2025 (abstract 7175). https:\/\/plan.core-apps.com\/astmh25\/abstract\/64a8399e-b1bb-4afb-befa-402b7f4a466a. Accessed Jun 2026."},{"key":"1428_CR29","unstructured":"Tai D, Mackenzie-Impoinvil L, Reimer L, et al. Transcriptomic insights into insecticide resistance in Aedes aegypti from Kingston and St. Andrew, Jamaica. Presented at ASTMH 2025 (abstract 7291). https:\/\/plan.core-apps.com\/astmh25\/abstract\/a48b5db3-0b26-47a3-a26d-14b9551b6bed. Accessed Jun 2026."},{"key":"1428_CR30","unstructured":"Nelson E, Ribeiro Dos Santos GR, Hitchings MDT, et al. The EVITA Dengue trial: drivers of sustained introgression of Wolbachia-infected Aedes aegypti in a complex urban setting. Presented at ASTMH 2025 (abstract 7170). https:\/\/plan.core-apps.com\/astmh25\/abstract\/41fb32ee-9921-4758-893a-c8c2f6fadb89. Accessed Jun 2026."},{"key":"1428_CR31","unstructured":"Finch E, Huang AT, Cortes-Azuero O. Optimising vaccination and Wolbachia interventions to control dengue in Brazil. Presented at ASTMH 2025 (abstract 6849). https:\/\/plan.core-apps.com\/astmh25\/abstract\/1be4271d-9087-45f6-acee-1984b4832d13. Accessed Jun 2026."},{"key":"1428_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101327","volume":"54","author":"BF de Morais","year":"2026","unstructured":"de Morais BF, Carcamo P, Nelson E, et al. The impact of large-scale release of Wolbachia mosquitoes on dengue incidence in Campo Grande, Brazil: an ecological study. Lancet Reg Health Am. 2026;54:101327. https:\/\/doi.org\/10.1016\/j.lana.2025.101327","journal-title":"Lancet Reg Health Am"},{"key":"1428_CR33","unstructured":"Carcamo PM, Dos Santos GR, Nelson E, et al. Introgression outcomes from Wolbachia-based interventions in Campo Grande, Brazil. Presented at ASTMH 2025 (abstract 6242). https:\/\/plan.core-apps.com\/astmh25\/abstract\/88de4b70-9487-49f5-8978-4e80d9689177. Accessed Jun 2026."},{"key":"1428_CR34","unstructured":"Hamins-Puertolas M, Bahr L, Buddhari D, et al. Characterizing the performance of a Meso Scale Discovery (MSD) based multiplexed serological assay to quantify antibody responses to multiple flaviviruses. Presented at ASTMH 2025 (abstract 6855). https:\/\/plan.core-apps.com\/astmh25\/abstract\/57769ee0-0fed-41ad-b8e9-9327122c35a6. Accessed Jun 2026."},{"key":"1428_CR35","unstructured":"Schulman RC, Rooney T, Middleton F. Detection of trace dengue virus in New York State through wastewater surveillance. Presented at ASTMH 2025 (abstract 7779). https:\/\/plan.core-apps.com\/astmh25\/abstract\/aa9fa421-ba48-48b2-a988-c17b0ee487bc. Accessed Jun 2026."},{"key":"1428_CR36","unstructured":"Passos-Castilho AM, Wilson C, Tipples G, et al. Travel-related dengue, zika and chikungunya in Canada, 2012\u20132023: results from a feasibility pilot study on laboratory-based surveillance. Presented at ASTMH 2025 (abstract 6103). https:\/\/plan.core-apps.com\/astmh25\/abstract\/9138101e-d418-4c45-a622-a8d1710e618b. Accessed Jun 2026."},{"issue":"21","key":"1428_CR37","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1056\/NEJMoa2500179","volume":"393","author":"AP Durbin","year":"2025","unstructured":"Durbin AP, Van Wesenbeeck L, Pierce KK, et al. Daily mosnodenvir as dengue prophylaxis in a controlled human infection model. N Engl J Med. 2025;393(21):2107\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2500179.","journal-title":"N Engl J Med"},{"key":"1428_CR38","unstructured":"Luna EJA, Campos SR. Brazil, 2024: 6.4 million probable dengue cases, but were they all really dengue? Presented at ASTMH 2025 (abstract 6847). https:\/\/plan.core-apps.com\/astmh25\/abstract\/6e96c567-ea60-4fc3-80ce-dc408ca271d2. Accessed Jun 2026."},{"key":"1428_CR39","unstructured":"Bustos Carrillo FA, Ojeda S, Sanchez LN, et al. A comparative analysis of dengue, chikungunya, and Zika manifestations in a pediatric cohort over 18 years. Presented at ASTMH 2025 (abstract 6693). https:\/\/plan.core-apps.com\/astmh25\/abstract\/739ec369-4f35-4e1b-b688-857169b98298. Accessed Jun 2026."},{"key":"1428_CR40","unstructured":"Valencia AM, Sy H, Vargas-Gonzalez DA, et al. Evaluation of nucleic acid amplification testing in saliva and urine for dengue diagnosis in Colombia. Presented at ASTMH 2025 (abstract 6069). https:\/\/plan.core-apps.com\/astmh25\/abstract\/a2e8340f-a4bf-4e8f-954a-330394be8e3e. Accessed Jun 2026"},{"key":"1428_CR41","unstructured":"World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/b1db05d8-0e97-469e-b529-464dca6de540\/content. Accessed Jun 2026."},{"key":"1428_CR42","unstructured":"Dhooria GS, Bhat D. Effect of 25% albumin in children with fluid refractory severe dengue on patient outcomes: a game changer. Presented at WSPID 2025 (ID 33). https:\/\/wspid2025.com\/abstract-e-book\/. Accessed Jun 2026."},{"key":"1428_CR43","unstructured":"Quang CH, Trung TH, Lyle NN, et al. Real-time haemodynamic assessment in dengue shock using continuous physiological monitoring. Presented at ASTMH 2025 (abstract 6691). https:\/\/plan.core-apps.com\/astmh25\/abstract\/022b35c1-8943-4e52-92d6-5e658e18deb6. Accessed Jun 2026."},{"key":"1428_CR44","unstructured":"Shahrin L, Alam T, Sarmin M, Chisti MJ, Shahid ASMSB. Tracking the tipping points: factors influencing progression to severe dengue in hospital during an upsurge. Presented at ASTMH 2025 (abstract 6172). https:\/\/plan.core-apps.com\/astmh25\/abstract\/6edf6cb1-0772-440d-8c3b-0b180b449beb. Accessed Jun 2026."},{"key":"1428_CR45","unstructured":"Tsai JJ, Li-Teh L, Huang SY, et al. Analysis of the associated risk factors for severe dengue during the 2023 dengue outbreak in Kaohsiung, Taiwan. Presented at ASTMH 2025 (abstract 6259). https:\/\/plan.core-apps.com\/astmh25\/abstract\/80f02e72-4764-4647-8839-a77fa563e4ac. Accessed Jun 2026."},{"issue":"2","key":"1428_CR46","doi-asserted-by":"publisher","DOI":"10.15190\/d.2024.8","volume":"12","author":"M Nasir","year":"2024","unstructured":"Nasir M, Irfan J, Asif AB, Khan QU, Anwar H. Complexities of dengue fever: pathogenesis, clinical features and management strategies. Discoveries (Craiova). 2024;12(2):e189. https:\/\/doi.org\/10.15190\/d.2024.8.","journal-title":"Discoveries (Craiova)"},{"key":"1428_CR47","unstructured":"Centers for Disease Control. Symptoms of dengue and testing. https:\/\/www.cdc.gov\/dengue\/signs-symptoms\/index.html. Accessed Jun 2026."},{"key":"1428_CR48","unstructured":"Rotejanaprasert C. Disaggregating dengue: a spatiotemporal analysis of dengue severity levels and their climatic and socioeconomic drivers in Thailand, 2003\u20132023. Presented at ASTMH 2025 (abstract 6814). https:\/\/plan.core-apps.com\/astmh25\/abstract\/163d0021-59ad-4ef9-84a4-8ba4644ee5ae. Accessed Jun 2026"},{"key":"1428_CR49","unstructured":"Choudhary B, Daya M, Gadepalli R, Singh K, Khera D. Role of POCUS in Early Prediction of the Severity of Dengue Infection in Pediatric Emergency. Presented at WSPID 2025 (ID 617). https:\/\/wspid2025.com\/abstract-e-book\/. Accessed Jun 2026."},{"key":"1428_CR50","unstructured":"Katzelnick L, Thomas S, Yacoub S, Rothman A, Salje H, Ooi EE. Looking in the mirror: revisiting preconceptions, assumptions, and dogma in dengue ecology, immunology, and epidemiology. Presented at ASTMH 2025 (session 169\u2014panel discussion). https:\/\/plan.core-apps.com\/astmh25\/event\/a6cd99a823d4323e69285cde4b49471d. Accessed Jun 2026."},{"key":"1428_CR51","unstructured":"Hardy CSC, Wegman A, Waldran MJ, Chan GC, Waickman A. Cell intrinsic mechanisms of antibody-dependent enhancement of dengue virus infection. Presented at ASTMH 2025 (abstract 6281). https:\/\/plan.core-apps.com\/astmh25\/abstract\/f69f7f40-6bef-46e8-ba61-90f0d7dc69f2. Accessed Jun 2026."},{"key":"1428_CR52","unstructured":"Bos S, Singh T, Zambrana JV, et al. Magnitude and long-term persistence of homotypic and heterotypic dengue virus antibodies across viral antigens and antibody isotypes. Presented at ASTMH 2025 (abstract 7460). https:\/\/plan.core-apps.com\/astmh25\/abstract\/0574b781-a2cf-4732-97aa-6853255ca7c6. Accessed Jun 2026."},{"key":"1428_CR53","unstructured":"Duarte EM, Chapa MA, Bal A, et al. Serotype-dependent variation in fusion loop antibody responses in dengue virus infections reveals asymmetry and association with disease outcome. Presented at ASTMH 2025 (abstract 7458). https:\/\/plan.core-apps.com\/astmh25\/abstract\/e5e6438c-d09f-4ffc-bfb0-a6e4a2721aa3. Accessed Jun 2026."},{"key":"1428_CR54","unstructured":"Townsend D, Singh T, Martins C, et al. Proteomic deconvolution of the plasma antibody response to secondary dengue virus infection. Presented at ASTMH 2025 (abstract 6604). https:\/\/plan.core-apps.com\/astmh25\/abstract\/d0ed8b36-5be8-44f2-92f2-a826a5b0b186. Accessed Jun 2026."},{"key":"1428_CR55","unstructured":"Jimenez I, Anderson KB, Thomas S, et al. Quantitative classification of primary versus secondary dengue infections using IgG and IgM antibody dynamics. Presented at ASTMH 2025 (abstract 7428). https:\/\/plan.core-apps.com\/astmh25\/abstract\/d7bf3fe8-9852-4216-8688-db64ca127f09. Accessed Jun 2026."},{"key":"1428_CR56","unstructured":"Camila O, Firdous S, Voirin CJ, et al. Phase 1 trial to safely model primary, secondary, and tertiary dengue. Presented at ASTMH 2025 (abstract 6646). https:\/\/plan.core-apps.com\/astmh25\/abstract\/1d026653-08ea-416e-b9da-466e18c486ae. Accessed Jun 2026."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01428-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01428-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01428-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:02:51Z","timestamp":1791954171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01428-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01428-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof. S\u00e1fadi declares that he has received research grants and consultancy fees from GSK, Pfizer, Sanofi, and Takeda and served as an independent member of a Data and Safety Monitoring Board for a clinical trial sponsored by Merck.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies. All referenced studies involving human participants were performed with appropriate ethical approval and in accordance with relevant ethical standards.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}